Screener
Intellia Therapeutics NTLA Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Intellia Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337952
FAQ
- What is Intellia Therapeutics's total liabilities?
- Intellia Therapeutics (NTLA) reported total liabilities of $129.46M in Q2 2026.
- How has Intellia Therapeutics's total liabilities changed year-over-year?
- Intellia Therapeutics's total liabilities decreased by 29.5% year-over-year, from $183.64M to $129.46M.
- What is the long-term trend for Intellia Therapeutics's total liabilities?
- Over 3 years (2022 to 2025), Intellia Therapeutics's total liabilities has grown at a -15.7% compound annual growth rate (CAGR), from $284.53M to $170.73M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Intellia Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude